BioNTech Wants To Develop A Malaria Vaccine For The African Continent


July 27, 2021, 3:34 p.m.

A German pharmaceutical group, BioNTech, wants to develop a malaria vaccine for the African continent with mRNA technology. This comes after BioNTech successfully developed the COVID vaccine with the US company Pfizer using the same mRNA technology.

The messenger Ribonucleic Acid or mRNA are medicines that act as sets of instructions. These instructions direct cells in the body to produce proteins that help prevent or fight diseases.

In 2019, about 409 000 people died from malaria, with children under five accounting for 67% of deaths according to WHO.

Do you have an article that can be relevant to the African Tech space?

Submit your news stories, articles or press releases to


"We will do whatever it takes to develop a safe and effective mRNA-based malaria vaccine that will prevent the disease, reduce mortality and ensure a sustainable solution for the African continent and other regions affected by this disease," BioNTech CEO Ugur Sahin said in a statement.

Sahin was quick to state that the project is at a very early stage, and there is no guarantee of success. Adding that the company believes that this is "the perfect time to address this challenge" because of the insights gained from developing an mRNA vaccine against Covid-19.

The Germany-based group said it aims to begin clinical malaria vaccine trials by the end of 2022.

tag: Health Tech, covid-19, technology,


Verny Joy Author

Verny loves to write poetry, fiction and quotes. Her love for writing landed her in journalism. She loves gadgets and travelling to explore new places.